Multiple Sclerosis Clinical Trial
Official title:
"Outwalk MS" - Benefits of Outdoor Walking Exercise Therapy on Walking Capacity and Well-being in Multiple Sclerosis
Verified date | November 2021 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Deterioration of walking capacity is a common symptom in persons with multiple sclerosis (pwMS), furthermore having a negative influence on well-being. Studies have nevertheless shown that walking exercise therapy can improve walking capacity in pwMS. This may be particularly potent if occurring outdoors due to the varying stimuli it can provide (different surfaces and terrain etc.), and if the intensity and duration is adequate. Furthermore, outdoor walking is (1) suitable as a group intervention facilitating interaction between pwMS and (2) advantageous due to the health benefits offered through the interaction with nature itself. Both these aspects are also relevant for well-being. Few studies have nevertheless examined the effects of outdoor walking exercise therapy in pwMS. The purpose of the present study is therefore to examine the effects of 7 weeks of moderate-to-high intensity outdoor walking exercise therapy on walking capacity (primary outcome: 6-minute walk test) and well-being in pwMS.
Status | Completed |
Enrollment | 60 |
Est. completion date | November 30, 2022 |
Est. primary completion date | July 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years - self-reported clinical MS diagnosis - PDDS = 4 (corresponding to preserved walking capacity without assistive devices of at least 10 m) - able to independently attend the testing Exclusion Criteria: - self-reported comorbidities excluding participation in the intervention - recent (6 months retrospective) fractures, amputation or other critical physical impairments that eliminates participation in the described training study - participation in structured exercise therapy (including walking) for the past 3 months (= 2 session per week of moderate-to-high intensity) |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University, Health, Exercise Biology | Aarhus | Jutland |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | The Danish MS Society |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6-minutes walk test (6MWT) | Maximal distance covered in 6 minutes using a 30 meter walkway. Assesses walking endurance. | Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | 6-minutes walk test (6MWT) | Maximal distance covered in 6 minutes using a 30 meter walkway. Assesses walking endurance. | Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Timed 25-foot walk test (T25FWT) | Time used to complete a 25-foot (= 7.62 meters) walk test. Two trials are given. Assesses horizontal walking propulsion/acceleration (i.e. walking speed). | Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Timed 25-foot walk test (T25FWT) | Time used to complete a 25-foot (= 7.62 meters) walk test. Two trials are given. Assesses horizontal walking propulsion/acceleration (i.e. walking speed). | Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Six spot step test (SSST) | Time used to complete the SSST (5 wooden blocks must be pushed/kicked outside their initial position). Four trials are given, two with each foot being used to push/kick the wooden blocks. Assesses horizontal coordination and dynamic balance during walking. | Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Six spot step test (SSST) | Time used to complete the SSST (5 wooden blocks must be pushed/kicked outside their initial position). Four trials are given, two with each foot being used to push/kick the wooden blocks. Assesses horizontal coordination and dynamic balance during walking. | Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | 12-item multiple sclerosis walking scale (MSWS-12) | Questionnaire (patient-reported outcome) assessing patient-reported impact of multiple sclerosis on walking ability.
Total score range 12-60 (0-100%); lower is better. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | 12-item multiple sclerosis walking scale (MSWS-12) | Questionnaire (patient-reported outcome) assessing patient-reported impact of multiple sclerosis on walking ability. 12 questions.
Total score range 12-60 (0-100%); lower is better. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Modified fatigue impact scale (MFIS) | Questionnaire (patient-reported outcome) assessing patient-reported perceived fatigue impact. 21 questions.
Total score range 0-84; lower is better. Physical subscale score range (9 questions) 0-36; lower is better. Cognitive subscale score range (10 questions) 0-40; lower is better. Psychosocial subscale score range (2 questions) 0-8; lower is better. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Modified fatigue impact scale (MFIS) | Questionnaire (patient-reported outcome) assessing patient-reported perceived fatigue impact. 21 questions.
Total score range 0-84; lower is better. Physical subscale score range (9 questions) 0-36; lower is better. Cognitive subscale score range (10 questions) 0-40; lower is better. Psychosocial subscale score range (2 questions) 0-8; lower is better. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Falls-efficacy scale (FES-I) | Questionnaire (patient-reported outcome) assessing concerns of falling along with history of falls.
7 questions. Total score range 0-28; lower is better. History of falls: one year recall. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Falls-efficacy scale (FES-I) | Questionnaire (patient-reported outcome) assessing concerns of falling along with history of falls.
7 questions. Total score range 0-28; lower is better. History of falls: one year recall. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | WHO five well-being index (WHO5) | Questionnaire (patient-reported outcome) assessing patient-reported well-being. 5 questions. Score range 0-25 (0-100%); higher is better. | Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | WHO five well-being index (WHO5) | Questionnaire (patient-reported outcome) assessing patient-reported well-being. 5 questions. Score range 0-25 (0-100%); higher is better. | Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | EuroQoL 5 dimensions 3 levels (EQ5D) | Questionnaire (patient-reported outcome) assessing patient-reported quality of life.
VAS scale score range 0-100%; higher is better. 5 domains, scored separately, score range 1-3; lower is better. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | EuroQoL 5 dimensions 3 levels (EQ5D) | Questionnaire (patient-reported outcome) assessing patient-reported quality of life.
VAS scale score range 0-100%; higher is better. 5 domains, scored separately, score range 1-3; lower is better. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Baecke physical activity questionnaire | Questionnaire (patient-reported outcome) assessing patient-reported participation in physical activities.
4 questions. Score range is continuous (0-xx). Higher is better. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Baecke physical activity questionnaire | Questionnaire (patient-reported outcome) assessing patient-reported participation in physical activities.
4 questions. Score range is continuous (0-xx). Higher is better. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) | |
Secondary | Patient-determined disease steps (PDDS) | Questionnaire (patient-reported outcome) assessing patient-reported disability in multiple sclerosis (MS).
9 questions/categories. Each category represents disability level; lower is better. |
Change from baseline (Pre) to after 7 weeks intervention (Post) | |
Secondary | Patient-determined disease steps (PDDS) | Questionnaire (patient-reported outcome) assessing patient-reported disability in multiple sclerosis (MS).
9 questions/categories. Each category represents disability level; lower is better. |
Change from baseline (Pre) to 24 weeks follow-up (Follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|